GVK BIO Enters into Drug Discovery Agreement With Wyeth Pharmaceuticals

by Thilaka Ravi on  May 26, 2008 at 3:11 PM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

 GVK BIO Enters into Drug Discovery Agreement With Wyeth Pharmaceuticals
GVK BIO today announced its entry into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover drug candidates focused on pre-defined discovery targets.

GVK BIO will utilise in-house capabilities in discovery chemistry, informatics, biology and ADME to advance this program.

GVK BIO will be responsible for identifying drug candidates, which will be transferred to Wyeth to advance these compounds towards clinical studies.

Under the agreement, GVK BIO will receive an initial payment and will be eligible for success-based milestone payments.

G V Sanjay Reddy, Managing Director, GVK Biosciences said, "It is a momentous occasion for us. GVK BIO has had a successful partnership with Wyeth on various chemistry research activities dating to 2006.

This research agreement expands our work together and builds on GVK BIO's core strengths. This agreement further validates India's capability to do innovative research along with leading pharmaceutical and biotech companies".

Source: ANI
THK/L

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Iodine Deficiency Disorder Clinical Trials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive